Category Archives: Investment

Healthcare stocks bounce back Friday after really messy week, but still licking their wounds from recent global selloff.

After having their worst week in recent memory, with the NASDAQ HealthCare Index (IXHC) now down 8.6% since just Sept. 28, some healthcare stocks nonetheless blossomed with stupendous upswings. But… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

Five more biotechs and one device maker close out 3rd quarter IPOs this week.

There are as many as five more biotech IPOs and one medical device maker pricing this week, raising up to $535 million. Even if two are postponed, it will still… Read more »

Flood gates for medical IPO filings still wide open as Labor Day holiday only speeds up pace for hopefuls.

The somber mood of summer’s waning days and shortened work week didn’t cool the blistering pace of biotech and other healthcare IPO news. Almost makes me feel sorry for the… Read more »

Weekly Medical Stock Spotlight: 3 big winners and 2 total duds.

1) ProQR Therapeutics NV (Nasdaq:PRQR) led advancing issues on the Labor Day-shortened week, soaring 107% over the week to $15.80 on Friday (August 31, 2018). The upward move came after the… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

Solution to China’s vaccine scandal now in the hands of rising blockchain maven VeChain. Buy a few tokens?

The News: A new production scandal has undermined Chinese citizens’ confidence in domestically made vaccines, and the tech community is suggesting the solution may lie in a highly touted technology: blockchain…. Read more »

Unknown Kentucky biotech Bexion tests new glioma med on first patients. Yes, it’s the same cancer Sen. McCain is fighting, and Round B funding is still open.

The News: Bexion Pharmaceuticals burst out of the shadows of near total obscurity last week as its investigational cancer treatment, BXQ-350, grabbed plenty of mainstream media coverage as a potential game-changer. BXQ-350 is… Read more »

Move over, Nasdaq: BeiGene’s mammoth IPO in Hong Kong sends message to biotech startups.

The News: Nasdaq-listed Chinese biotech BeiGene Ltd. (Beijing) has raised an astounding $903 million after pricing its secondary listing in Hong Kong–the first under new exchange rules–near the top of… Read more »

With a frenzy of popping corks and champagne toasts, Sangamo bags French biotech TxCell as Europe’s CAR T-cell science expanding into autoimmune disease. SGMA is a buy.

The News: Sangamo Therapeutics Inc. (Richmond CA) has acquired TxCell SA (Valbonne FRA) with a view toward utilizing its chimeric antigen receptor (CAR) technology to prevent organ transplant rejections and treat… Read more »